Professor of medical oncology at the University Claude Bernard Lyon I and the General Director of the Centre Léon Bérard in Lyon, France.

Prof. Blay received his medical degree from the Université Claude Bernard Lyon 1 in 1990. He performed oncology and internal medicine training at the Université Claude Bernard Lyon 1 and at the Institut Gustave-Roussy in Paris. At the completion of his fellowship, he joined the staff of the Comprehensive Cancer Center Léon Bérard in Lyon. In 1994, he received a PhD from the Université Claude Bernard Lyon 1 and became the head of the Cytokine and Cancer Unit within an INSERM research unit in 1996, now Team 11 of the INSERM U1052 of the CRCL.

He was the network director of the CONTICANET, a Network of Excellence funded by the 6th Framework Program of the European commission (, serves currently as project director for the EUROSARC project, and as president of the French Sarcoma Group ( He has served as vice chairman of both the Protocol Review Committee and the Translational Research Advisory Committee of the European Organisation for Research and Treatment of Cancer (EORTC) and also as the chairman of the Soft Tissue and Bone Sarcoma Group of EORTC. Between 2009 and 2012, he served as the president of EORTC and is currently serving as Past President. Prof. Blay is also head of the Reference Network for Sarcoma in France (French National Cancer Institute), a faculty member of the European Society for Medical Oncology (ESMO) Sarcoma group, and a board member of the French Society of Cancer (SFC).

Prof Blay’s research interests focus on clinical and basic research in sarcomas, the biology of breast carcinoma, and the relation between tumor microenvironment and malignant cells, to improve the diagnosis, prognosis, and treatment of these diseases. Prof. Blay has published over 400 peer-reviewed articles and numerous other abstracts and book chapters.



Dr Bizzari holds a medical degree from the University of Nice (France) and trained as an oncologist at the Pitie Salpetriere hospital in Paris.

He continued his training in Toronto (Ontario Cancer Institute – Canada) and Montreal (Mac Gill Cancer Center – Canada) before joining the pharmaceutical industry in 1983 as Head of Oncology at the Institut de Recherches Internationales SERVIER (France). In 1993, he joined Rhone-Poulenc Rorer as Vice President of Clinical Oncology, based in Paris and subsequently moved to Collegeville (PA – USA) in 1997. With the merger of Rhone-Poulenc Rorer with HMR (to form Aventis), he was responsible for the Oncology Clinical Development at Aventis as Vice President. From April 2002 until September 2008, he was the Vice President of Clinical Development, Oncology, of sanofi-aventis in Malvern, PA. Dr. Bizzari joined Celgene in October 2008 as Senior Vice President, Clinical Development Oncology. He was the Executive Vice President of Clinical Development in Celgene and was responsible for the development of Revlimid, Vidaza, Pomalidomide and Abraxane. Some of Dr. Bizzari’s past accomplishments include, the Clinical Development of several anti-cancer agents such as: Fotemustine, Taxotere, Irinotecan, Gliadel and Eloxatin. Dr. Bizzari has also been involved in the development of numerous cytostatics compounds such as anti-angiogenics (VEGF-trap), gene therapy, vaccines and bio-reductive agents. He has published more than 70 articles in peer review journals and more than 160 abstracts in scientific congresses.

Dr. Bizzari’s research interests include the methodology of clinical trials, clinical development of non-cytotoxic agents and PK/PD analysis.



Prof. Depil is Senior Vice President Research & Development and Chief Medical Officer at Cellectis. In addition to this role, Stéphane Depil is onco-hematologist at Léon Bérard Cancer Center, adjunct Professor at University Claude Bernard Lyon 1, France, and Vice President of Immuno-Oncology group at Unicancer.

Prof. Depil is a Board-certified physician in hematology and has over 15 years of experience in oncology clinical development, both in hospital / university and pharmaceutical companies. He obtained a PhD in immunology at Institut de Biologie de Lille after working on a project of cancer vaccination.

Prior to joining the Léon Bérard Cancer Center & Cancer Research Center of Lyon, as Medical Director of the Cancer Immunotherapy Program, he served as Chief Executive Officer at NETRIS Pharma. Prior to NETRIS Pharma, Prof. Depil worked at Servier for 8 years in a variety of roles, including Director of Oncology Research and Development, where he managed 20 programs. He also directly supervised the evaluation of over 100 licensing opportunities.



Dr. Bredesen received his undergraduate degree from Caltech and his medical degree from Duke. He served as Resident and Chief Resident in Neurology at UCSF, then was postdoctoral fellow in the laboratory of Nobel laureate Prof. Stanley Prusiner. Following this he became a faculty member at UCLA from 1989-1994 and then was recruited by the Burnham Institute to direct the Program on Aging. In 1998 he became the Founding President and CEO of the Buck Institute for Research on Aging, and Adjunct Professor at UCSF; then in 2013 he returned to UCLA as the Director of the Easton Center for Alzheimer’s Disease Research.

The Bredesen Laboratory studies basic mechanisms underlying the neurodegenerative process, and the translation of this knowledge into effective therapeutics for Alzheimer’s disease and other neurodegenerative conditions, which has led to the publication of over 200 research papers.

He introduced the notion of dependence receptor while he was working on the low affinity receptor p75ntr and have shown the importance of this notion in neurodegenerative diseases.



Jean-Charles Soria is a Professor of Medicine and Medical Oncology at South-Paris University. He is a tenure-track and full-time cancer specialist at Institut Gustave Roussy. Dr Soria trained as a medical oncologist and obtained the Silver medal from Paris Medical School in 1997. He gained a PhD degree in the fundamental basis of oncogenesis in 2001, and completed his training with a two-year post-doctoral fellowship in the Department of Thoracic Head and Neck Medical Oncology at MD Anderson Cancer Center, Houston, USA, where he has held an Adjunct Professorship since 2012.

Professor Soria is currently Chair of Drug Development Department at Gustave Roussy Cancer Center in Paris and is a member of the lung cancer unit with a focus on targeted therapies. He is the Director of the SIRIC program at Gustave Roussy. His main research interests are: early clinical development, phase I trials across solid tumors, pharmacodynamic biomarkers, lung cancer and personalized medecine. He is also involved in translational research aspects related to precision medicine and tumor progression notably in lung cancer models (INSERM unit 981). Dr Soria was a member of ESMO Executive Committee from 2008 to 2009, and has served as an ASCO committee member from 2006 to 2012. He was the scientific chairman of the ECCO-ESMO 2011 meeting that was held in Stockholm in 2011, and chair of the EORTC-NCI-AACR meeting in Barcelona in 2014, co-chair in EORTC-NCI-AACR meeting in Boston in 2015 and chair of the EORTC-NCI-AACR meeting in Munich in 2016. He was the President of the TAT meeting in 2013 and 2015 in Paris.

He has contributed to over 480 peer-reviewed publications, including publications as first or last author in the New England Journal of Medicine, the Journal of the National Cancer Institute, and the Journal of Clinical Oncology. He has been appointed as Editor in Chief of Annals of Oncology for the period 2014-2018